Kymera Investor Presentation Deck slide image

Kymera Investor Presentation Deck

Preferred Term Nausea ALT increased AST increased Constipation Fatigue Stomatitis Anemia Number of Patients with Adverse Event Occurring in ≥15 Patients Overall (n, (%) Dose Level 1 0.05 mg/kg (n=4) Dose Level 2 0.1 mg/kg (n=4) All Related Dose Level 3 0.2 mg/kg (n=5) All Related Dose Level 4 0.4 mg/kg (n=11) All Related 3 (27.3) 1 (9.1) Dose Level 5 0.7 mg/kg (n=5)a All Related Related All 1 (25.0) 1 (25.0) 3 (60.0) 2 (40.0) 4 (36.4) 3 (27.3) 2 (50.0) KT-333: Overall Safety Profile 2 (50.0) 1 (25.0) 1 (25.0) 2 (50.0) 2 (40.0) 2 (40.0) 1 (20.0) KYMERA ©2023 KYMERA THERAPEUTICS, INC. 1 (20.0) 1 (20.0) 3 (27.3) 3 (27.3) 2 (18.2) 3 (27.3) 2 (18.2) 2 (18.2) 1 (9.1) 3 (27.3) 1 (9.1) 1 (9.1) Abdominal pain 2 (50.0) 1 (25.0) a At the time of data cut off DL5 was still open to enrollment in patients with solid tumors and lymphoma diagnosis with an expected enrollment total of n=6 b All Grade 1 2 (40.0) 2 (40.0) 1 (20.0) 3 (60.0) 1 (20.0) 2 (40.0) Overall (N=29) All 8 (27.6) 8 (27.6) 7 (24.1) 1 (20.0) 7 (24.1) 7 (24.1) 3 (60.0) 7 (24.1) 6 (20.7) 5 (17.2) Related 1 (3.4) 3 (10.3)b 2 (6.9)b 1 (3.4) 2 (6.9) 6 (20.7) 1 (3.4) 1 (3.4) Summary: At the time of the data cut-off (October 18, 2023), KT-333 was well tolerated, with primarily grade 1 and 2 AEs; 2 DLTs observed in LGL-L patients at DL5, no DLTs in solid/lymphomas at any dose level PAGE 45
View entire presentation